BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 29783777)

  • 1. Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.
    Gangrade A; Pathak V; Augelli-Szafran CE; Wei HX; Oliver P; Suto M; Buchsbaum DJ
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
    Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
    Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
    Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
    Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel recombinant human Frizzled-7 protein exhibits anti-tumor activity against triple negative breast cancer via abating Wnt/β-catenin pathway.
    Xie W; Zhang Y; He Y; Zhang K; Wan G; Huang Y; Zhou Z; Huang G; Wang J
    Int J Biochem Cell Biol; 2018 Oct; 103():45-55. PubMed ID: 30096373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saikosaponin D from Radix Bupleuri suppresses triple-negative breast cancer cell growth by targeting β-catenin signaling.
    Wang J; Qi H; Zhang X; Si W; Xu F; Hou T; Zhou H; Wang A; Li G; Liu Y; Fang Y; Piao HL; Liang X
    Biomed Pharmacother; 2018 Dec; 108():724-733. PubMed ID: 30248540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual targeting of Notch and Wnt/β-catenin pathways: Potential approach in triple-negative breast cancer treatment.
    Nasser F; Moussa N; Helmy MW; Haroun M
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Mar; 394(3):481-490. PubMed ID: 33052427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/β-catenin and mTORC1 signaling in prostate and breast cancer cells.
    Lu W; Lin C; Li Y
    Cell Signal; 2014 Jun; 26(6):1303-9. PubMed ID: 24607787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced lncRNA Aim enhances the malignant invasion of triple-negative breast cancer cells mainly by activating Wnt/β-catenin/mTOR/PI3K signaling.
    Liu L; Yu D; Shi H; Li J; Meng L
    Pharmazie; 2017 Oct; 72(10):599-603. PubMed ID: 29441885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
    Zhang WL; Ma WJ; Chen S; Wu XZ; Zhang HR; Zhang JH
    Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):578-88. PubMed ID: 27531477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
    Lu W; Lin C; Roberts MJ; Waud WR; Piazza GA; Li Y
    PLoS One; 2011; 6(12):e29290. PubMed ID: 22195040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gigantol inhibits Wnt/β-catenin signaling and exhibits anticancer activity in breast cancer cells.
    Yu S; Wang Z; Su Z; Song J; Zhou L; Sun Q; Liu S; Li S; Li Y; Wang M; Zhang GQ; Zhang X; Liu ZJ; Lu D
    BMC Complement Altern Med; 2018 Feb; 18(1):59. PubMed ID: 29444668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells.
    Lu W; Li Y
    J Cell Biochem; 2014 Oct; 115(10):1799-807. PubMed ID: 24905570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prodigiosin inhibits Wnt/β-catenin signaling and exerts anticancer activity in breast cancer cells.
    Wang Z; Li B; Zhou L; Yu S; Su Z; Song J; Sun Q; Sha O; Wang X; Jiang W; Willert K; Wei L; Carson DA; Lu D
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13150-13155. PubMed ID: 27799526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells.
    Li Y; Oliver PG; Lu W; Pathak V; Sridharan S; Augelli-Szafran CE; Buchsbaum DJ; Suto MJ
    Cancer Lett; 2017 Mar; 389():41-48. PubMed ID: 28043913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P; Carlson JH; Wu H; Marcus A; Leyland-Jones B; Dey N
    Oncotarget; 2016 Jul; 7(28):43124-43149. PubMed ID: 27281609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.
    Ryu WJ; Lee JD; Park JC; Cha PH; Cho YH; Kim JY; Sohn JH; Paik S; Choi KY
    Exp Mol Med; 2020 May; 52(5):832-842. PubMed ID: 32457491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
    Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
    PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
    Shen H; Yan W; Yuan J; Wang Z; Wang C
    J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P; Carlson JH; Jepperson T; Willis S; Leyland-Jones B; Dey N
    Oncotarget; 2017 Jan; 8(2):3072-3103. PubMed ID: 27902969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.
    Arend RC; Londoño-Joshi AI; Gangrade A; Katre AA; Kurpad C; Li Y; Samant RS; Li PK; Landen CN; Yang ES; Hidalgo B; Alvarez RD; Straughn JM; Forero A; Buchsbaum DJ
    Oncotarget; 2016 Dec; 7(52):86803-86815. PubMed ID: 27888804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.